Restoring the diversity of stem cells to reverse aging in bones
Reversing Skeletal Aging by Restoring Functional Skeletal Stem Cell Diversity
['FUNDING_OTHER'] · UNIVERSITY OF CALIFORNIA AT DAVIS · NIH-11004168
This study is looking at how getting older changes the special cells that help keep our bones healthy, with the hope of finding ways to improve their function and prevent bone problems like osteoporosis in older adults.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA AT DAVIS (nih funded) |
| Locations | 1 site (DAVIS, UNITED STATES) |
| Trial ID | NIH-11004168 on ClinicalTrials.gov |
What this research studies
This research investigates how aging affects skeletal stem cells, which are crucial for maintaining bone health. It aims to identify and restore the diversity of these stem cells to improve their function and combat age-related bone diseases like osteoporosis. By analyzing the molecular changes in these cells at a single-cell level, the research seeks to understand how aging alters their ability to regenerate bone. The ultimate goal is to develop effective therapies that can prevent or treat skeletal diseases in older adults.
Who could benefit from this research
Good fit: Ideal candidates for this research are older adults experiencing age-related bone health issues, particularly those at risk for osteoporosis.
Not a fit: Patients who are younger and do not have any age-related bone health concerns may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve bone health and reduce the risk of fractures in older adults.
How similar studies have performed: Previous research has shown promise in using stem cell therapies for bone regeneration, indicating that this approach could be effective.
Where this research is happening
DAVIS, UNITED STATES
- UNIVERSITY OF CALIFORNIA AT DAVIS — DAVIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: AMBROSI, THOMAS HANS — UNIVERSITY OF CALIFORNIA AT DAVIS
- Study coordinator: AMBROSI, THOMAS HANS
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.